![itziar_erkizia_edited.jpg](/sites/default/files/styles/1_1_small/public/imports/dest/drupal7_imatges/itziar_erkizia_edited.jpg?h=1f3fdc12&itok=zF2KlgRi)
Itziar Erkizia Jauregi
Tècnic/a sènior de laboratori
Grup de recerca
Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy.
Impact of obefazimod on viral persistence, inflammation, and immune activation in people with HIV on suppressive antiretroviral therapy.
Author Correction to: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells.
Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide.
Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry.